AMV-564 is under clinical development by Amphivena Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AMV-564’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AMV-564 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AMV-564 is under development for the treatment of relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome and solid tumors including adenocarcinoma of the gastroesophageal junction, endometrial cancer, rectal cancer, penile cancer, transitional cell cancer (urothelial cell cancer), squamous cell carcinoma and non-small cell lung cancer. The drug candidate is a CD33/CD3 tetravalent bi-specific tandem antibody which comprises of two VH and Vl amino acid chains that form four antigen-binding single-chain variable fragment. It is administered through the intravenous and subcutaneous routes. The drug candidate based on TandAb technology, a bi-specific antibody platform designed for immune therapy of cancer.
Amphivena Therapeutics overview
Amphivena Therapeutics is a clinical-stage, immuno-oncology company. The company is developing a novel platform of dual-function biologics that relieve immune suppression and drive T-cell activation and polarization to restore anti-cancer immunity in patients. The company is headquartered in South San Francisco, California, the US.
Quick View AMV-564 LOA Data
|Highest Development Stage|